Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

CRISPR Therapeutics shares are trading higher after Citizens reiterated its Market Outperform rating and maintained a $80 price target.

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

Moderna Borrows $2 Billion To Expand Oncology Business

Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.

EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer

Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.